InvestorsHub Logo
Followers 14
Posts 4677
Boards Moderated 0
Alias Born 11/13/2003

Re: kookiekook post# 370

Monday, 02/27/2012 3:37:39 AM

Monday, February 27, 2012 3:37:39 AM

Post# of 554
Friends, I have been doing a little reading and extrapolating from the Qnexah experience with the FDA panel and wonder if a scenario similar might be in the future for Cue10Zah.

When Vivas produced its drug, it failed its clinical testings and was not approved. During the testing, however, some unintended consequences were noted; to wit, while it didn't perform as intended for the condition it was supposed to treat, it did produce some results for another ailment. So, the pharmacologists did their work and resubmitted the product for approval to treat something else. The FDA panel voted to approve the drug for the treatment of the other malady discovered as an unintended consequent.

Maybe NGSX's Cue10Zah might not be efficacious for pain management to the FDA standards, but, as a wag elsewhere has proposed, the product instead of being hot chili pepper juice on a patch could be modified as an erectile dysfunction treatment by placing Cue10Zah inside a condom. Thoughts?

If capsaisin doesn't do the job to gain FDA approval for pain management, tweaking its app might make it useful to solve some other problem. All IMHO.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.